CD20 Antibody Primes B Lymphocytes for Type I
Interferon Production by Xu, Dongsheng et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Faculty Publications in the Biological Sciences Papers in the Biological Sciences
2013







University of Nebraska - Lincoln, lzhang2@unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/bioscifacpub
Part of the Biology Commons
This Article is brought to you for free and open access by the Papers in the Biological Sciences at DigitalCommons@University of Nebraska - Lincoln.
It has been accepted for inclusion in Faculty Publications in the Biological Sciences by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Xu, Dongsheng; Staedman, Andrew; and Zhang, Luwen, "CD20 Antibody Primes B Lymphocytes for Type I Interferon Production"
(2013). Faculty Publications in the Biological Sciences. 341.
http://digitalcommons.unl.edu/bioscifacpub/341
CD20 Antibody Primes B Lymphocytes for Type I
Interferon Production
Dongsheng Xu1¤, Andrew Staedman2, Luwen Zhang1,2*
1 School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, United States of America, 2 Nebraska Center for Virology, University of Nebraska,
Lincoln, Nebraska, United States of America
Abstract
CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas.
Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and
other diseases. However, CD20 antibody failed to treat systemic lupus erythematosus (SLE or lupus). The reason for
the failure is currently unknown. Type I interferons (IFN) are a major component for the host innate immunity, and a
key pathogenic factor in lupus. We found that CD20 antibody potentiated human B cells for its production of IFNs in
vitro. This function was specific to CD20-expressing cells and the potentiation function seems to be instant. In
addition, ectopic expression of CD20 in non-B-lymphocytes increased the IFN promoter reporter activities. Because
IFNs are a key pathogenic factor in lupus, our data suggest that, in the presence of virus infection, the CD20-
antibody-mediated enhancement of IFN production might be related to its failure in lupus treatments. This work may
provide new insights for CD20-Ab therapeutic applications.
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Introduction
Systemic lupus erythematosus (SLE), also called lupus, is a
chronic systemic autoimmune disease that affects about 0.1%
of the US population, and results in inflammation and damage
to a range of organ systems including joints, muscles and other
parts of the body.
Human type I Interferons (IFN) consist of 13 distinct IFN-α
and other subtypes [1,2]. IFNs are apparently a hallmark in
lupus. IFN levels and IFN-stimulated genes, collectively called
IFN signatures in some of the literature, are elevated in lupus
patients [3–8]. The use of IFNs for the treatment of other
diseases has caused lupus-like syndromes [9,10]. In rodent
models of lupus, mice have failed to develop lupus
manifestations if the IFN receptor is deleted [11]. IFN promotes
survival and differentiation of mature lymphocytes, class
switching at immunoglobulin heavy chain loci, and activation of
dendritic cells (DC) [12]. Finally, IFN enhances the activation of
B lymphocytes by RNA-associated autoantigens [13]. Thus, the
IFN pathway has emerged as a focal point for understanding
mechanisms of autoimmunity in lupus.
CD20 is a 33–37 kDa membrane-associated and non-
glycosylated phosphoprotein expressed on the surface of all
mature B-cells [14,15]. CD20 plays a role in the development
and differentiation of B-cells into plasma cells. The CD20
protein has no known natural ligand and its function is very
elusive [14,15]. It is suspected that CD20 acts as a calcium
channel in the cell membrane [16]. In addition, recent data
suggest that CD20 may play a central role in the generation of
T cell-independent antibody responses [17].
The CD20 antibodies, such as rituximab, Ibritumomab
tiuxetan, and tositumomab, are all active agents in the
treatment of some B cell lymphomas and leukemias [18,19].
Interestingly, recent randomized placebo-controlled trials failed
to demonstrate the efficacy of Rituximab in patients with SLE
[20–23]. Many reasons might explain the failure, such as the
small number of patients, the relatively short follow-up time,
and the use of relatively high doses of other medicines [24].
Others suggested that anti-inflammatory strategies, not just B
cell depletion, may be required for optimal therapy for SLE [25].
We were testing if the CD20-Ab affects Epstein–Barr virus
(EBV)-mediated transformation of human B lymphocytes, and
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in the process, we found that CD20-Ab, or rituximab,
potentiated B lymphocytes for the production of IFNs. This
work suggested that CD20 might be a component of innate
immunity in B lymphocytes. Because IFN is a key pathogenic
determinant for lupus [3,26–28], the potentiation of B
lymphocytes for IFN production might be related to the failure
of the lupus treatment with the antibody [20–23].
Materials and Methods
Plasmids, viruses, and antibodies
CD20 expression plasmid was purchased from Addgene
(Plasmid 1890). The IFN-β-promoter reporter constructs were
gift from Dr. Rutuan Lin. Sendai virus stock was purchased
from Spafas, Inc. For virus infection, 200 HA units/ml Sendai
virus were added to the target cells for 6 h, and cells were then
collected for RNA isolation. Vesicular stomatitis virus (VSV),
Indiana strain, was a gift from Dr. Asit Pattnaik. Rituximab
(CD20 antibody) was purchased from Genetech. Anti-Sendai
virus antibody was purchased from U.S. Biological (Cat#:
S0700).
Cell Culture, Transient Transfection, and Reporter
Assays
293T is a human fibroblast line, and was grown in
Dulbecco’s modified Eagle medium (DMEM, Gibco BRL)
supplemented with 10% fetal bovine serum (FBS; Gibco BRL)
and 1% Penicillin-streptomycin (PS) at 37 °C in 5% CO2
incubation. DG75, IB4 and LCL are all B cell lines. THP1 is a
monocyte line and Jurkat is a T cell line. All those cells were
maintained in RPMI-1640 plus 10% FBS. Effectene (Qiagen)
was used for the transfection of 293T following Manufacturer’s
recommendation. The luciferase reporter assays were
performed using the assay kit from Promega according to
manufacturer’s recommendation.
RNA Extraction and RNase Protection Assays (RPA)
Total RNA was isolated from cells using the RNeasy total
RNA isolation kit (Qiagen, Valencia, CA) or TRIzol extraction
methods. RPA was performed with 10 µg of total RNA using
the RNase protection assay kit II (Ambion, Houston, TX) at 55
°C [29–31]. Sometimes, gradient temperatures were performed
for RPA when difficulties in RPA were encountered [32]. The
GAPDH probe was purchased from U.S. Biochemicals. The
probe for IFN-β was a gift from Dr. Ganes Sen.
Western Blot Analysis with Enhanced
Chemiluminescence (ECL)
Separation of proteins on SDS-PAGE was carried out
following standard protocol. After the proteins were transferred
to a nitrocellulose or Immobilon membrane, the membrane was
blocked with 5% nonfat dry milk in TBST (50 mm Tris-HCl, pH
7.5, 200 mm NaCl, 0.05% Tween 20) at room temperature for
10 min. It was then washed briefly with TBST and incubated
with the primary antibody in 5% milk in TBST for 1 h at room
temperature or overnight at 4 °C. After washing with TBST
three times (10 min each), the membrane was incubated with
the secondary antibody at room temperature for 1 h. It was
then washed three times with TBST, treated with ECL detection
reagents (Amersham Biosciences), and exposed to Kodak
XAR-5 film.
IFN-α Measurement
The concentration of IFN-α was determined by a
commercially available human interferon α (Hu-IFN-α) ELISA
kit (PBL Biomedical Laboratories; catalog number 41100)
according to the manufacturer’s recommendations. The kit is
able to detect human IFN-αA, IFN-α2, IFN-αA/D, IFN-αD, IFN-
αK, and IFN-α4b. However, it cannot detect IFN-β, IFN-ω, and
other IFN-α subtypes. Samples were examined in duplicates.
Results
Rituximab potentiates B lymphocytes for IFN
productions
Rituximab is a humanized antibody against CD20, and it is
used successfully for the treatment of B lymphomas. We
suspect that the CD20 antibody may affect B cell biology and
therefore affect the production of IFNs upon viral infection. IB4
is a commonly used B cell line transformed by EBV in vitro
[33–38]. Rituximab (10µg/ml) was used to treat cells and at the
same time, the Sendai virus was used to infect the cells. The
use of 10µg/ml Rituximab is common in the field [39–41]. As
shown in the Figure 1A, IFN production was enhanced when
the CD20-Ab was used. Type I IFNs have multiple subtypes
[42]; however, the use of IFN-β as an indicator for type I IFNs
production is well-established and appreciated in the field. To
eliminate the possibility that Rituximab enhances the viral
replication and thus the IFN production, we did examine the
viral replication by detection of the Sendai viral protein
expression. As shown in Figure 1B, the expression of viral
protein was not enhanced with the treatment of CD20 antibody
(Figure 1B). To eliminate the effect of EBV in the enhanced IFN
production, we have used other B cell line that lack of EBV
infection. DG75 is an EBV-negative Burkitts’ lymphoma line. As
shown in Figure 1C, IFN production was also enhanced, and
the viral protein expressions were not increased upon the
CD20 Ab treatments (Figure 1D). Therefore, CD20-Ab
enhances cells for the production of IFNs upon viral infection.
The effects of Rituximab on IFN productions is specific
for B lymphocytes
To test if the potentiation effect of the CD20 Ab is B
lymphocyte specific, we have treated several cell lines with
different cell lineages. LCL is another EBV-transformed B
lymphocytes at early passages, and no mutation are expected
for the line. Jurkat is a T cell line and THP1 is a monocyte line.
The same experimental procedures were used for those lines,
and Sendai virus was used for induction of IFNs. As shown in
Figure 2, while CD20 has potentiation effects on LCL, the
effects were not present for THP1 and Jurkat cells. Therefore,
the effects of Rituximab on IFN productions are likely specific
for B lymphocytes.
CD20 Antibody and Interferon
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Time and dosage effects on Rituximab mediated effects
on IFN productions
We further examined dose and time requirements for the
enhancement. Different amounts of CD20 Ab were used with
Sendai virus simultaneously. As shown in Figure 3A, there
seemed to be a dose response to the CD20-Ab. However, the
dosage of 10µg/ml, commonly used in the field [39–41], is
sufficient to enhance IFN production. In addition, the CD20-Ab
was used to treat cells for various times, then infect with
Sendai virus and the RNA were isolate 6 hours later for IFNs
detection. As shown in Figure 3B, longer time exposure to the
Figure 1.  Rituximab enhances cells for the production of IFN-β.  A. IB-4 is a commonly used EBV transformed B cells. The
cells were treated with rituximab (10 mg/ml) and at the same time, were infected by Sendai virus (200 HA units/ml) for 6 h. Total
RNAs were isolated and used for RPA with IFN-βand GAPDH probes. Yeast RNA was used as negative control. Specific
protections of IFN-β and GAPDH RNAs are indicated. B. Sendai virus protein expression. Different amounts of Rituximab and
constant. Sendai (200 HA units/ml) were used to treat cells simultaneously for 6 hours. Cell lysates were used for detection of viral
replication. Specific viral proteins and GAPDH are as shown. C and D: DG75 cells are EBV-negative Burkitts’ lymphoma cells and
were treated with Rituximab and Sendai virus simultaneously for 6 hours. IFN-β productions were measured in C, and Sendai viral
protein expression was determined in D.
doi: 10.1371/journal.pone.0067900.g001
CD20 Antibody and Interferon
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CD20-Ab is actually detrimental for the enhancement. The
reduction might be related to apoptosis as the CD20-Ab
treatment may induce apoptosis [43]. The data also suggest
that the enhancement of IFN production is likely to be an early
event in Rituximab treatment.
CD20 expression enhanced IFN activation
To test if CD20 expression in non-B lymphocytes would
enhance these cells for IFN production, we have transfected
CD20 expression plasmid into 293T cells along with IFN-β-
promoter reporter construct. As shown in Figure 4A, while
CD20 itself has limited effect on the promoter activity, the
Sendai virus induced activation of the promoter reporter was
enhanced, in agreement with the previous data.
Other virus can also induce IFN production
The Sendai virus was chosen because it is the most
commonly used virus for IFN induction studies. The use of
Sendai virus for IFN production was well established and
appreciated in the field. However, to avoid the possibility that
the potentiation effect of CD20Ab was a virus specific
phenomenon, we tested whether the CD20-Ab enhanced
another virus-induced IFN production. Vesicular stomatitis virus
(VSV) was used and it is known the virus activates IFN
pathway through toll-like receptor 7 (TLR7) pathway [44]. VSV
infect B cells poorly, so we used ELISA to monitor the IFN
production after 24 hours of infection. As shown in Figure 4B,
CD20-Ab enhances the production of IFNs by VSV.
Surprisingly, the CD20-Ab itself might induce low levels of IFNs
(lane 3), the result of which can be obtained consistently in two
cell lines (data not shown). The data suggested that different
virus can have the similar effects on IFN production upon CD20
treatments.
Discussion
Innate immunity is important to control viral infection, but
over-activation of the innate immunity may lead to autoimmune
diseases. IFNs are a key component of host innate immunity.
CD20 antibodies represent a class of successful drugs that
used for treatment of lymphomas. Interestingly, IFN has been
employed in the treatment of lymphomas with various degrees
of success. Some clinical data have reported additive or
Figure 2.  The specificity of the Rituximab treatment for IFN enhancement.  LCL is another EBV-transformed B cell line. THP-1
is a human acute monocytic leukemia cell line; and Jurkat is an immortalized line of T lymphocyte cells. All these cells were treated
with Rituximab and Sendai virus simultaneously for 6 hours. IFN-β productions were measured. Specific protections of IFN-β and
GAPDH RNAs are indicated.
doi: 10.1371/journal.pone.0067900.g002
CD20 Antibody and Interferon
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synergistic activity of IFN with rituximab in treatment of
lymphomas [45–47]. While many studies are centered the
CD20 antibodies on tumor control, whether the antibodies have
any effects on host innate immunity is unknown.
In this report, we studied the effects of CD20 antibody on
innate immunity, specifically type I IFN productions. We find
that: 1) CD20 antibody could potentiate the production of type I
IFNs, and the potentiation is not related to viral replications
(Figure 1); 2) The potentiation effect seems to be specific to B
lymphocytes that express CD20 molecules (Figure 2); 3) The
effects of CD20 antibody is apparently instant, and no
pretreatments are needed (Figure 3); 4) The virus choices are
not a factor for the potentiation effect (Figure 4B). All those
Figure 3.  Dose and time-dependent enhancement of the IFN-production by Rituximab.  A. Different amounts of Rituximab and
constant Sendai virus (200 HA units/ml) were used to treat IB-4 cells simultaneously. The RNA was isolated after 6 hours and RPA
was used for detection of IFN productions. B. the IB4 cells were treated with 10 mg/ml Rituximab with indicated time, Sendai was
then used to infect the cells. The RNA was isolated after 6 hours and RPA was used for detection of IFN productions. Specific
protections of IFN-β and GAPDH RNAs are indicated.
doi: 10.1371/journal.pone.0067900.g003
Figure 4.  A. CD20 expression enhances IFN promoter reporter activity.  293T cells were transfected with IFN-β promoter
reporter constructs and expression plasmid of CD20 (0.1, and 0.2 mg). After the overnight incubation, Sendai virus (20 HA units/ml)
was added and the luciferase and β-galactosidase activities were measured 24 hours later. The relative fold of activation was
calculated as a ratio of luciferase over β-galactosidase activities. Standard deviations are as shown. B. Rituximab enhances VSV-
induced IFN-α production. IB4 cells were treated with VSV (M.O.I=1) and Rituximab. 24 hours later, medium was collected for
ELISA for IFN-α (multiple subtypes) measurements. Samples were measured in duplications, and the average of duplications is as
shown.
doi: 10.1371/journal.pone.0067900.g004
CD20 Antibody and Interferon
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data collectively indicates that CD20-Ab potentiates the
production of type I IFNs in B lymphocytes.
Interestingly, CD20 antibody alone may induce low-levels of
IFN-α (Figure 4B). The apparent differences between Figure
4B and Figures 1-3 in terms of IFN production may be due to
the fact that only six hours treatment were used for Figures 1-3,
but 24 hours were used for Figure 4B. In addition, a mixture of
IFN-α subtypes, rather than IFN-β, was determined in Figure
4B. Of note, the clinical data suggest that the IFN pathways are
activated in the CD20 antibody treatment [48–50]. Those data
suggest that the CD20Ab may activate low levels of IFNs both
in vivo and in vitro.
As TLR pathways are critical for lupus pathogenesis, we had
tested if TLR3, TLR7, or TLR9 agonists (dsRNA, imiquimod,
and ODN2395 respectively) and CD20 antibody for IFN
induction, the enhancement by CD20-Ab was not observed
(data not shown). It is known VSV-mediated IFN production is
via TLR7 [44], but why TLR7 agonist (imiquimod) failed to
induce IFNs in these B cell lines is not clear [51].
As a cellular gene, CD20 may have its own function. It is
obvious that the function of CD20 is still elusive as one can
delete the gene from mouse genome without obvious effect
[52], and there is no ligand identified so far for the CD20
antigen. We suspect that the putative ligand binding to CD20,
or the expression of CD20 alone, may be imitated and/or
enhanced by CD20 and its Ab interactions. It is known that
CD20 has calcium-channel activity and the function is
stimulated by the CD20-Ab treatment [53]. In addition, ectopic
expression of CD20 in a non-B cell line enhances IFN-β-
promoter activity upon virus infection (Figure 4A). The data
suggest that CD20 might be a component for IFN production in
B lymphocytes.
The Rituximab was failed for the treatment of lupus patients
with several explanations [20–25]. With our data in this report,
we suspect that CD20 Ab may potentiate IFNs production in B
lymphocytes in vivo by virus infections in lupus patients.
Although a potentiation effect was not observed by TLR
agonists (data not shown), lupus patients do have virus
infections. For example, EBV is strongly associated with lupus
and viral load is increased with the disease flares [54,55]. As
IFNs are a key pathogenic factor for lupus pathogenesis, this
research may provide possible mechanism for the failure of
Rituximab in the treatment of lupus: the potentiation for IFN
production as well as the low level induction of IFNs by CD20-
Ab alone (Figures 1 and 4B). Although CD20-Ab may induce
apoptosis in B lymphocytes, but at the same time, the IFN
productions it might enhanced in vivo, may counteract the
depletion effects of B cells. In essence, the report here may
support the notion that anti-inflammatory strategies, not just B
cell depletion, may be required for optimal therapy for SLE [25].
Rheumatoid arthritis (RA) is the most common chronic
inflammatory disorder of the musculoskeletal system that may
cause permanent joint damage. A beneficial role for type I IFN
in RA has been identified [56,57]. Rituximab is approved
worldwide for the treatment of RA, and highly beneficial in
decreasing clinical symptoms, safe, and well tolerated.
However, approximately 30-40% of RA patients do not respond
to it. Genome-wide gene expression profiling of whole
peripheral blood cells of RA patients shows that type I IFN
response genes expression is associated with a good clinical
response, whereas the IFN-response activity did not change or
slightly decreased in the non-responders [48–50]. Our data
suggest that an additional factor in RA patients may usurp the
potentiation function and for the expression of IFN genes and
therefore the IFN responsive genes.
In summary, we have discovered another function for the
CD20 antibody, i.e., to potentiate B lymphocytes for type I IFN
production. In the presence of virus infection, this potentiation
function as well as the low level induction of IFNs by CD20-Ab
alone (Figure 4B) suggest that a novel mechanism for the
failure of the CD20-Ab treatment of lupus patients.
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